LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.2 EUR | -2.49% |
|
+2.18% | +36.54% |
| 04-02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| 03-12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Evolution of the average Target Price on Laboratorios Farmaceuticos Rovi, S.A.
Price target over the last 5 years
History of analyst recommendation changes
f85951364955db582047cf47738fb.3JRBfkNlzyNkr8dwpWektI0nVBsYC9iIu_O-DDLVUWo.tuExOSk3oGdJwvdCzhbn7MJ2GUt7br--_oLkRkDgNRKaxQBHFDeddCf1ng~4a5d65996432bd642d7619551f570287
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
82.2
EUR
Average target price
85.12
EUR
Spread / Average Target
+3.56%
High Price Target
100
EUR
Spread / Highest target
+21.65%
Low Price Target
66
EUR
Spread / Lowest Target
-19.71%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B+
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROVI Stock
- Consensus Laboratorios Farmaceuticos Rovi, S.A.
